In our two-part interview, Cytel consulting statistician Ursula Garczarek reveals how rare disease development is benefitting from adaptive trial approaches. In this episode, Ursula shares her insights on current international regulatory perspectives. Ursula draws from he own considerable experiences, including defending adaptive trial statistical methodologies and their performance before EMA and FDA regulators.
All content for Cytel Podcasts is the property of Cytel and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In our two-part interview, Cytel consulting statistician Ursula Garczarek reveals how rare disease development is benefitting from adaptive trial approaches. In this episode, Ursula shares her insights on current international regulatory perspectives. Ursula draws from he own considerable experiences, including defending adaptive trial statistical methodologies and their performance before EMA and FDA regulators.
Cytel Announces Availability of EnForeSys 2.0 More than half of today’s clinical studies take longer than expected to achieve their enrollment targets, often leading to discontinued trials and expensive failures. EnForeSys is the decision tool using modern simulation methods to accurately predict recruitment milestones. Armed with a reliable probability of success, rest assured your trial will achieve target enrollment on time and on budget. New features “Interactive Planner" mode for iterati...
Cytel Podcasts
In our two-part interview, Cytel consulting statistician Ursula Garczarek reveals how rare disease development is benefitting from adaptive trial approaches. In this episode, Ursula shares her insights on current international regulatory perspectives. Ursula draws from he own considerable experiences, including defending adaptive trial statistical methodologies and their performance before EMA and FDA regulators.
